Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLYM Climb Bio	$1.21 -0.8%	$1.24	$1.05 ▼ $9.58	$81.77M	-0.12	275,486 shs	109,509 shs
ONTX Onconova Therapeutics		$0.85	$0.55 ▼ $1.45	$20.90M	1.38	96,681 shs	1.28 million shs
PLRX Pliant Therapeutics	$1.38 +0.7%	$1.41	$1.10 ▼ $16.10	$84.71M	1.43	1.11 million shs	2.67 million shs
VTYX Ventyx Biosciences	$1.68 -7.5%	$1.25	$0.78 ▼ $5.66	$128.80M	0.73	1.34 million shs	1.27 million shs

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLYM Climb Bio	-0.82%	+2.54%	-9.70%	-16.55%	+120,999,900.00%
ONTX Onconova Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
PLRX Pliant Therapeutics	+0.73%	+6.98%	-13.21%	-59.88%	-89.06%
VTYX Ventyx Biosciences	-7.46%	-0.89%	+25.94%	+6.01%	-66.02%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CLYM Climb Bio	2.8346 of 5 stars	3.7	0.0	0.0	0.0	1.9	2.5	1.3
ONTX Onconova Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PLRX Pliant Therapeutics	4.3593 of 5 stars	4.0	3.0	0.0	4.7	2.2	1.7	0.6
VTYX Ventyx Biosciences	3.1283 of 5 stars	3.4	3.0	0.0	0.0	4.1	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CLYM Climb Bio	3.33	Buy	$8.50	602.48% Upside
ONTX Onconova Therapeutics	0.00	N/A	N/A	N/A
PLRX Pliant Therapeutics	2.00	Hold	$13.31	864.67% Upside
VTYX Ventyx Biosciences	2.75	Moderate Buy	$10.00	497.01% Upside

Current Analyst Ratings Breakdown

Latest ONTX, PLRX, CLYM, and VTYX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/22/2025	CLYM Climb Bio	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
5/22/2025	CLYM Climb Bio	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$7.00
3/18/2025	PLRX Pliant Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
3/4/2025	PLRX Pliant Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$4.00 ➝ $1.50
3/4/2025	PLRX Pliant Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
3/4/2025	PLRX Pliant Therapeutics	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Perform ➝ Sector Perform	$4.00 ➝ $3.00
3/4/2025	PLRX Pliant Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral
3/4/2025	PLRX Pliant Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$4.00 ➝ $3.00
3/4/2025	PLRX Pliant Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold	$10.00 ➝ $10.00
3/3/2025	PLRX Pliant Therapeutics	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
3/3/2025	PLRX Pliant Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold

(Data available from 5/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CLYM Climb Bio	N/A	N/A	N/A	N/A	$3.90 per share	N/A
ONTX Onconova Therapeutics	$230K	0.00	N/A	N/A	$1.35 per share	0.00
PLRX Pliant Therapeutics	$1.58M	53.62	N/A	N/A	$7.91 per share	0.17
VTYX Ventyx Biosciences	N/A	N/A	N/A	N/A	$4.13 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CLYM Climb Bio	-$35.12M	-$2.38	N/A	N/A	N/A	N/A	-42.21%	-41.39%	8/13/2025 (Estimated)
ONTX Onconova Therapeutics	-$18.96M	-$0.91	N/A	N/A	N/A	-8,930.97%	-95.43%	-61.19%	N/A
PLRX Pliant Therapeutics	-$161.34M	-$3.61	N/A	N/A	N/A	N/A	-48.91%	-41.09%	8/6/2025 (Estimated)
VTYX Ventyx Biosciences	-$192.96M	-$1.75	N/A	N/A	N/A	N/A	-54.94%	-50.01%	8/14/2025 (Estimated)

Latest ONTX, PLRX, CLYM, and VTYX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	CLYM Climb Bio	-$0.15	-$0.31	-$0.16	-$0.31	N/A	N/A
5/8/2025	Q1 2025	VTYX Ventyx Biosciences	-$0.48	-$0.39	+$0.09	-$0.39	N/A	N/A
3/25/2025	Q4 2024	CLYM Climb Bio	-$0.15	-$0.13	+$0.02	-$0.13	N/A	N/A
3/3/2025	Q4 2024	PLRX Pliant Therapeutics	-$0.99	-$0.82	+$0.17	-$0.82	$0.08 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CLYM Climb Bio	N/A	N/A	N/A	N/A	N/A
ONTX Onconova Therapeutics	N/A	N/A	N/A	N/A	N/A
PLRX Pliant Therapeutics	N/A	N/A	N/A	N/A	N/A
VTYX Ventyx Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CLYM Climb Bio	N/A	57.73	57.73
ONTX Onconova Therapeutics	N/A	2.79	2.79
PLRX Pliant Therapeutics	0.09	10.26	10.26
VTYX Ventyx Biosciences	N/A	23.52	23.52

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CLYM Climb Bio	69.76%
ONTX Onconova Therapeutics	7.95%
PLRX Pliant Therapeutics	97.30%
VTYX Ventyx Biosciences	97.88%

Insider Ownership

Company	Insider Ownership
CLYM Climb Bio	0.80%
ONTX Onconova Therapeutics	3.30%
PLRX Pliant Therapeutics	8.00%
VTYX Ventyx Biosciences	14.49%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CLYM Climb Bio	9	67.58 million	65.07 million	N/A
ONTX Onconova Therapeutics	16	21.00 million	20.31 million	Optionable
PLRX Pliant Therapeutics	90	61.39 million	56.96 million	Optionable
VTYX Ventyx Biosciences	30	71.16 million	57.86 million	Optionable

ONTX, PLRX, CLYM, and VTYX Headlines

Recent News About These Companies

Ventyx Biosciences, Inc. (NASDAQ:VTYX) Shares Acquired by Two Sigma Advisers LP

May 31 at 3:55 AM | marketbeat.com

Woodline Partners LP Purchases Shares of 213,240 Ventyx Biosciences, Inc. (NASDAQ:VTYX)

May 29 at 4:19 AM | marketbeat.com

Ventyx Biosciences to Participate in the Jefferies Global Healthcare Conference

May 28 at 8:00 AM | globenewswire.com

Bank of America Corp DE Has $9.36 Million Holdings in Ventyx Biosciences, Inc. (NASDAQ:VTYX)

May 26, 2025 | marketbeat.com

Point72 Asset Management L.P. Takes $3.90 Million Position in Ventyx Biosciences, Inc. (NASDAQ:VTYX)

May 22, 2025 | marketbeat.com

Vestal Point Capital LP Acquires 275,000 Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX)

May 21, 2025 | marketbeat.com

Ventyx Biosciences, Inc. (NASDAQ:VTYX) Shares Sold by Deerfield Management Company L.P. Series C

May 10, 2025 | marketbeat.com

Ventyx Biosciences Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Progress

May 8, 2025 | globenewswire.com

Why Ventyx Biosciences, Inc.’s (VTYX) Stock Is Down 6.88%

May 7, 2025 | aaii.com

Susquehanna Fundamental Investments LLC Buys Shares of 198,947 Ventyx Biosciences, Inc. (NASDAQ:VTYX)

May 6, 2025 | marketbeat.com

Great week for Ventyx Biosciences, Inc. (NASDAQ:VTYX) institutional investors after losing 70% over the previous year

May 4, 2025 | finance.yahoo.com

Ventyx Biosciences (VTYX) Projected to Post Quarterly Earnings on Thursday

May 3, 2025 | marketbeat.com

Boothbay Fund Management LLC Has $690,000 Stock Holdings in Ventyx Biosciences, Inc. (NASDAQ:VTYX)

May 2, 2025 | marketbeat.com

Renaissance Technologies LLC Acquires 310,800 Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX)

April 30, 2025 | marketbeat.com

Ventyx Biosciences announces seven additional appointments to SAB

April 2, 2025 | markets.businessinsider.com

Ventyx Biosciences Expands SAB with Renowned NLRP3 Experts and Prominent Neurodegenerative and Cardiometabolic Disease Specialists

April 1, 2025 | globenewswire.com

Ventyx Biosciences Reports 2024 Financial Results and Progress

March 4, 2025 | tipranks.com

Ventyx Biosciences Faces Supply Chain Risks Amidst U.S.-China Tensions and Regulatory Challenges

March 1, 2025 | tipranks.com

H.C. Wainwright Sticks to Their Hold Rating for Ventyx Biosciences (VTYX)

February 28, 2025 | markets.businessinsider.com

Ventyx Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Corporate Progress

February 27, 2025 | globenewswire.com

Ventyx Biosciences Announces Presentation of Data from the Phase 2 Trial of Allosteric TYK2 Inhibitor VTX958 in Crohn’s Disease at ECCO 2025

February 18, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ONTX, PLRX, CLYM, and VTYX Company Descriptions

Climb Bio NASDAQ:CLYM

$1.21 -0.01 (-0.82%)

As of 05/30/2025 04:00 PM Eastern

Climb Bio Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. Climb Bio Inc., formerly known as Eliem Therapeutics Inc., is based in WELLESLEY, Mass.

Onconova Therapeutics NASDAQ:ONTX

Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer in the United States. It has two clinical-stage programs, including narazaciclib, a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa study for the treatment of progressive K-Ras mutated non-small cell lung cancer. The company also conducting a Phase II investigator-initiated study with rigosertib monotherapy in patients with advanced/metastatic squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa. It has a license and collaboration agreement with HanX Biopharmaceuticals, Inc. for the development, registration, and commercialization of narazaciclib in China. Onconova Therapeutics, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.

Pliant Therapeutics NASDAQ:PLRX

$1.38 +0.01 (+0.73%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$1.36 -0.02 (-1.81%)

As of 05/30/2025 04:57 PM Eastern

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Ventyx Biosciences NASDAQ:VTYX

$1.68 -0.14 (-7.46%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$1.76 +0.08 (+4.78%)

As of 05/30/2025 07:10 PM Eastern

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time